In 15 people, one CRISPR infusion aimed at ANGPTL3 cut LDL 52.5% and triglycerides 47.8% at one year

What the research found

Study (phase 1, small). Luke J. Laffin, Steven E. Nissen, and colleagues at Cleveland Clinic report one-year follow-up of CTX310 in the New England Journal of Medicine (doi 10.1056/NEJMc2609825; presented at the 2026 European Society of Cardiology meeting; ScienceDaily 27 September 2026). Fifteen people with lipid disorders that had not responded adequately to usual care received a single infusion of a CRISPR-Cas9 editor delivered to the liver to switch off ANGPTL3, a gene that helps keep fats in the blood. Doses ranged from 0.1 to 0.8 mg/kg. At the highest dose, LDL cholesterol was 52.5% lower and triglycerides 47.8% lower at 12 months versus baseline. No serious events related to CTX310 were reported in that year. The product remains experimental. Researchers plan 15 years of safety follow-up. The work was funded by CRISPR Therapeutics. Educational notes. This is not available care and is not a reason to stop a lipid plan.

Evidence level: Clinical trial. This is among the stronger kinds of evidence, but one study rarely settles a question.

Read the original at Cleveland Clinic / New England Journal of Medicine